The prevalence of thrombotic events in patients with myeloproliferative neoplasms can be as high as 39% in some cases.
Current clinical data are insufficient to confirm or deny the potential association between risk for VTE and testosterone therapy.
Though the majority of patients with cutaneous T cell lymphomas experience pruritus, the pathophysiology of the symptom is relatively unclear.
Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.
Recent research suggests that vitamin D deficiency may negatively influence outcomes after hematopoietic stem cell transplantation.